Barclays PLC Buys 30,095 Shares of Akoya Biosciences, Inc. (NASDAQ:AKYA)

Barclays PLC grew its stake in shares of Akoya Biosciences, Inc. (NASDAQ:AKYA) by 320.9% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 39,472 shares of the company’s stock after acquiring an additional 30,095 shares during the period. Barclays PLC owned about 0.08% of Akoya Biosciences worth $107,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Regal Investment Advisors LLC raised its stake in shares of Akoya Biosciences by 64.3% during the second quarter. Regal Investment Advisors LLC now owns 18,760 shares of the company’s stock valued at $44,000 after acquiring an additional 7,340 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of Akoya Biosciences by 16.2% during the second quarter. Bank of New York Mellon Corp now owns 67,468 shares of the company’s stock valued at $158,000 after acquiring an additional 9,429 shares in the last quarter. GSA Capital Partners LLP raised its stake in shares of Akoya Biosciences by 87.4% during the third quarter. GSA Capital Partners LLP now owns 310,669 shares of the company’s stock valued at $845,000 after acquiring an additional 144,903 shares in the last quarter. Finally, State Street Corp raised its stake in shares of Akoya Biosciences by 4.2% during the third quarter. State Street Corp now owns 453,296 shares of the company’s stock valued at $1,233,000 after acquiring an additional 18,361 shares in the last quarter. Institutional investors own 79.42% of the company’s stock.

Akoya Biosciences Stock Performance

Shares of AKYA stock opened at $3.23 on Friday. Akoya Biosciences, Inc. has a 12-month low of $1.88 and a 12-month high of $6.31. The business’s fifty day simple moving average is $2.45 and its 200-day simple moving average is $2.58. The company has a current ratio of 2.75, a quick ratio of 1.85 and a debt-to-equity ratio of 5.62. The company has a market cap of $160.11 million, a PE ratio of -2.74 and a beta of 1.18.

Analysts Set New Price Targets

Several research firms have recently weighed in on AKYA. Canaccord Genuity Group downgraded shares of Akoya Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 13th. Piper Sandler reissued an “overweight” rating and issued a $3.00 price objective (down previously from $4.00) on shares of Akoya Biosciences in a research note on Tuesday, November 19th. Finally, Craig Hallum downgraded shares of Akoya Biosciences from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $7.00 to $5.00 in a research note on Friday, November 15th. Five research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $5.43.

Akoya Biosciences Profile

Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.